2018-2023 Global Low Molecular Weight Heparin Consumption Market Report

Published On: Oct 2018

Format: PDF

Publisher: LP Information

Pages: 134

Report ID: 174177

In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Low Molecular Weight Heparin market for 2018-2023.

Low Molecular Weight Heparin (LMWHs) is derived from UFH (Unfractionated heparin) by such processes as chemical degradation, enzymatic depolymerisation and gamma-radiation cleavage.
Natural heparin consists of molecular chains of varying lengths, or molecular weights. Chains of varying molecular weights, from 5000 to over 40,000 Daltons, make up polydisperse pharmaceutical-grade heparin. LMWHs, in contrast, consist of only short chains of polysaccharide. LMWHs are defined as heparin salts having an average molecular weight of less than 8000 Da and for which at least 60% of all chains have a molecular weight less than 8000 Da.
In 2016, in term of volume, the global Low molecular weight heparin market is led by china, capturing about 49.57% of global low molecular weight heparin production. In term of revenue, USA is the second’s largest market with the share of 30.49%.
At present, the major manufacturers of Low Molecular Weight Heparin are Aspen, Sanofi-aventis, Pfizer, Opocrin, CSBIO, Dongying Tiandong Pharmaceutical, Changzhou Qianhong Bio-pharma, Techdow, Yantai Dongcheng Pharmaceutical Group, etc. Aspen, Sanofi-aventis and Pfizer are industry-leading manufacturers of top-quality Low Molecular Weight Heparins.
China is a big low molecular weight heparin production country, especially Heparin API, but it is not strong country. According to our research and analysis, manufacturers from United States and Europe are the major leaders in the international market of low molecular weight heparin. Manufacturers from China are immature in technology. There is large space in the China market, as well as big gap between international brands and local brands on price.
In application, low molecular weight heparin downstream is wide and recently low molecular weight heparin has acquired increasing significance in various fields of treatment of venous thromboembolism, complications of pregnancy, cardioversion of atrial fibrillation/flutter and others.
Globally, the low molecular weight heparin market is mainly driven by growing demand for treatment of venous thromboembolism which accounts for nearly 65.24% of total downstream consumption of low molecular weight heparin in global.
Over the next five years, LPI(LP Information) projects that Low Molecular Weight Heparin will register a 5.6% CAGR in terms of revenue, reach US$ 380 million by 2023, from US$ 270 million in 2017.

This report presents a comprehensive overview, market shares, and growth opportunities of Low Molecular Weight Heparin market by product type, application, key manufacturers and key regions.

To calculate the market size, LP Information considers value and volume generated from the sales of the following segments:

Segmentation by product type:
Enoxaparin
Dalteparin
Tinzaparin
Fraxiparine
Segmentation by application:
Treatment of Venous Thromboembolism
Complications of Pregnancy
Cardioversion of Atrial Fibrillation/Flutter
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:
Aspen
Sanofi-aventis
Pfizer
Opocrin
CSBIO
Dongying Tiandong Pharmaceutical
Changzhou Qianhong Bio-pharma
Techdow
Yantai Dongcheng Pharmaceutical Group

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Low Molecular Weight Heparin consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
To understand the structure of Low Molecular Weight Heparin market by identifying its various subsegments.
Focuses on the key global Low Molecular Weight Heparin manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Low Molecular Weight Heparin with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Low Molecular Weight Heparin submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

Table of Contents

2018-2023 Global Low Molecular Weight Heparin Consumption Market Report

1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Low Molecular Weight Heparin Consumption 2013-2023
2.1.2 Low Molecular Weight Heparin Consumption CAGR by Region
2.2 Low Molecular Weight Heparin Segment by Type
2.2.1 Enoxaparin
2.2.2 Dalteparin
2.2.3 Tinzaparin
2.2.4 Fraxiparine
2.3 Low Molecular Weight Heparin Consumption by Type
2.3.1 Global Low Molecular Weight Heparin Consumption Market Share by Type (2013-2018)
2.3.2 Global Low Molecular Weight Heparin Revenue and Market Share by Type (2013-2018)
2.3.3 Global Low Molecular Weight Heparin Sale Price by Type (2013-2018)
2.4 Low Molecular Weight Heparin Segment by Application
2.4.1 Treatment of Venous Thromboembolism
2.4.2 Complications of Pregnancy
2.4.3 Cardioversion of Atrial Fibrillation/Flutter
2.4.4 Others
2.5 Low Molecular Weight Heparin Consumption by Application
2.5.1 Global Low Molecular Weight Heparin Consumption Market Share by Application (2013-2018)
2.5.2 Global Low Molecular Weight Heparin Value and Market Share by Application (2013-2018)
2.5.3 Global Low Molecular Weight Heparin Sale Price by Application (2013-2018)

3 Global Low Molecular Weight Heparin by Players
3.1 Global Low Molecular Weight Heparin Sales Market Share by Players
3.1.1 Global Low Molecular Weight Heparin Sales by Players (2016-2018)
3.1.2 Global Low Molecular Weight Heparin Sales Market Share by Players (2016-2018)
3.2 Global Low Molecular Weight Heparin Revenue Market Share by Players
3.2.1 Global Low Molecular Weight Heparin Revenue by Players (2016-2018)
3.2.2 Global Low Molecular Weight Heparin Revenue Market Share by Players (2016-2018)
3.3 Global Low Molecular Weight Heparin Sale Price by Players
3.4 Global Low Molecular Weight Heparin Manufacturing Base Distribution, Sales Area, Product Types by Players
3.4.1 Global Low Molecular Weight Heparin Manufacturing Base Distribution and Sales Area by Players
3.4.2 Players Low Molecular Weight Heparin Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Low Molecular Weight Heparin by Regions
4.1 Low Molecular Weight Heparin by Regions
4.1.1 Global Low Molecular Weight Heparin Consumption by Regions
4.1.2 Global Low Molecular Weight Heparin Value by Regions
4.2 Americas Low Molecular Weight Heparin Consumption Growth
4.3 APAC Low Molecular Weight Heparin Consumption Growth
4.4 Europe Low Molecular Weight Heparin Consumption Growth
4.5 Middle East & Africa Low Molecular Weight Heparin Consumption Growth

5 Americas
5.1 Americas Low Molecular Weight Heparin Consumption by Countries
5.1.1 Americas Low Molecular Weight Heparin Consumption by Countries (2013-2018)
5.1.2 Americas Low Molecular Weight Heparin Value by Countries (2013-2018)
5.2 Americas Low Molecular Weight Heparin Consumption by Type
5.3 Americas Low Molecular Weight Heparin Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries

6 APAC
6.1 APAC Low Molecular Weight Heparin Consumption by Countries
6.1.1 APAC Low Molecular Weight Heparin Consumption by Countries (2013-2018)
6.1.2 APAC Low Molecular Weight Heparin Value by Countries (2013-2018)
6.2 APAC Low Molecular Weight Heparin Consumption by Type
6.3 APAC Low Molecular Weight Heparin Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries

7 Europe
7.1 Europe Low Molecular Weight Heparin by Countries
7.1.1 Europe Low Molecular Weight Heparin Consumption by Countries (2013-2018)
7.1.2 Europe Low Molecular Weight Heparin Value by Countries (2013-2018)
7.2 Europe Low Molecular Weight Heparin Consumption by Type
7.3 Europe Low Molecular Weight Heparin Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa
8.1 Middle East & Africa Low Molecular Weight Heparin by Countries
8.1.1 Middle East & Africa Low Molecular Weight Heparin Consumption by Countries (2013-2018)
8.1.2 Middle East & Africa Low Molecular Weight Heparin Value by Countries (2013-2018)
8.2 Middle East & Africa Low Molecular Weight Heparin Consumption by Type
8.3 Middle East & Africa Low Molecular Weight Heparin Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.2 Low Molecular Weight Heparin Distributors
10.3 Low Molecular Weight Heparin Customer

11 Global Low Molecular Weight Heparin Market Forecast
11.1 Global Low Molecular Weight Heparin Consumption Forecast (2018-2023)
11.2 Global Low Molecular Weight Heparin Forecast by Regions
11.2.1 Global Low Molecular Weight Heparin Forecast by Regions (2018-2023)
11.2.2 Global Low Molecular Weight Heparin Value Forecast by Regions (2018-2023)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.5.6 Spain Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Low Molecular Weight Heparin Forecast by Type
11.8 Global Low Molecular Weight Heparin Forecast by Application

12 Key Players Analysis
12.1 Aspen
12.1.1 Company Details
12.1.2 Low Molecular Weight Heparin Product Offered
12.1.3 Aspen Low Molecular Weight Heparin Sales, Revenue, Price and Gross Margin (2016-2018)
12.1.4 Main Business Overview
12.1.5 Aspen News
12.2 Sanofi-aventis
12.2.1 Company Details
12.2.2 Low Molecular Weight Heparin Product Offered
12.2.3 Sanofi-aventis Low Molecular Weight Heparin Sales, Revenue, Price and Gross Margin (2016-2018)
12.2.4 Main Business Overview
12.2.5 Sanofi-aventis News
12.3 Pfizer
12.3.1 Company Details
12.3.2 Low Molecular Weight Heparin Product Offered
12.3.3 Pfizer Low Molecular Weight Heparin Sales, Revenue, Price and Gross Margin (2016-2018)
12.3.4 Main Business Overview
12.3.5 Pfizer News
12.4 Opocrin
12.4.1 Company Details
12.4.2 Low Molecular Weight Heparin Product Offered
12.4.3 Opocrin Low Molecular Weight Heparin Sales, Revenue, Price and Gross Margin (2016-2018)
12.4.4 Main Business Overview
12.4.5 Opocrin News
12.5 CSBIO
12.5.1 Company Details
12.5.2 Low Molecular Weight Heparin Product Offered
12.5.3 CSBIO Low Molecular Weight Heparin Sales, Revenue, Price and Gross Margin (2016-2018)
12.5.4 Main Business Overview
12.5.5 CSBIO News
12.6 Dongying Tiandong Pharmaceutical
12.6.1 Company Details
12.6.2 Low Molecular Weight Heparin Product Offered
12.6.3 Dongying Tiandong Pharmaceutical Low Molecular Weight Heparin Sales, Revenue, Price and Gross Margin (2016-2018)
12.6.4 Main Business Overview
12.6.5 Dongying Tiandong Pharmaceutical News
12.7 Changzhou Qianhong Bio-pharma
12.7.1 Company Details
12.7.2 Low Molecular Weight Heparin Product Offered
12.7.3 Changzhou Qianhong Bio-pharma Low Molecular Weight Heparin Sales, Revenue, Price and Gross Margin (2016-2018)
12.7.4 Main Business Overview
12.7.5 Changzhou Qianhong Bio-pharma News
12.8 Techdow
12.8.1 Company Details
12.8.2 Low Molecular Weight Heparin Product Offered
12.8.3 Techdow Low Molecular Weight Heparin Sales, Revenue, Price and Gross Margin (2016-2018)
12.8.4 Main Business Overview
12.8.5 Techdow News
12.9 Yantai Dongcheng Pharmaceutical Group
12.9.1 Company Details
12.9.2 Low Molecular Weight Heparin Product Offered
12.9.3 Yantai Dongcheng Pharmaceutical Group Low Molecular Weight Heparin Sales, Revenue, Price and Gross Margin (2016-2018)
12.9.4 Main Business Overview
12.9.5 Yantai Dongcheng Pharmaceutical Group News

13 Research Findings and Conclusion